OPKO Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on January 24, 2012, covering events occurring on January 20, 2012. The filing details the entry into a Material Definitive Agreement to acquire a Chilean pharmaceutical distributor.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The primary financial data relates to the proposed acquisition:
- Total Purchase Price: $4.0 million
- Cash at Closing: $2.4 million (less certain liabilities)
- Escrow Deposit: $0.8 million (held for potential indemnity claims)
- Contingent Payment: $0.8 million (payable upon legal registration of specific trademarks and product registrations)
Material Changes
On January 20, 2012, OPKO Health, Inc. and its wholly-owned subsidiary, OPKO Chile S.A., entered into a Stock Purchase Agreement to acquire 100% of the issued and outstanding shares of ALS Distribuidora Limitada ("ALS"). ALS is a privately-held Chilean company engaged in the importation, commercialization, and distribution of pharmaceutical products for private markets. The acquisition includes all product registrations, trademarks, and the "Arama" name previously held by Arama Laboratorios y Compania Limitada.
Outlook and Management Commentary
The acquisition is expected to close during the first quarter of 2012. The transaction is intended to expand the Company's presence in the Chilean pharmaceutical market by acquiring an established distributor with operations dating back to 2009. The agreement includes customary representations, warranties, conditions to closing, and indemnification provisions.
Investor Verification Checklist
- Verify the closing date of the acquisition within the first quarter of 2012.
- Confirm the successful legal registration of the trademarks and product registrations required to trigger the $800,000 contingent payment.
- Review the specific liabilities deducted from the initial $2.4 million cash payment at closing.
- Assess the integration plan for ALS into OPKO's existing operations in Chile.